Clinical Trial

Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2006-04-26; most recent amendment 2023-08-24.
Status change: Recruiting → Active, Not Recruiting 2018-03-08
Trial Details
NCT Number NCT00319228
Lead Sponsor Grifols Biologicals, LLC
Conditions Antithrombin III Deficiency
Enrollment 30 participants
Start Date 2006-01
Primary Completion 2028-12 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2023-08-25